managing anaemia in ibd
play

Oxford Inflammatory Bowel Disease & Hepatology MasterClass Managing Anaemia in IBD Dr Alex Kent Senior Research Fellow Disclosures WHO Classification of Anaemia Normal haemoglobin and haematocrit levels Population group Haemoglobin

0 downloads 2 Views 329 KB Size Report
  1. Oxford Inflammatory Bowel Disease & Hepatology MasterClass Managing Anaemia in IBD Dr Alex Kent Senior Research Fellow

  2. Disclosures

  3. WHO Classification of Anaemia Normal haemoglobin and haematocrit levels Population group Haemoglobin Haematocrit g/dL Mmol/L % Children 6 mo – 5 years 11.0 6.83 33 Children 5-11 years 11.5 7.13 34 Children 12-14 years 12.0 7.45 36 Non-pregnant women 12.0 7.45 36 Pregnant women 11.0 6.83 33 Men 13.0 8.07 39 WHO/UNICEF/UNU. Iron deficiency anemia: Assessment, prevention and control. Report of a joint WHO/UNICEF/UNU consultation. Geneva; World Health Organisation, 1998

  4. Impact of anaemia “asymptomatic”  Reduced quality of life: equalling cancer 1  Higher disease activity 2 : reduced hct & general well-being  Chronic fatigue  Impaired cognitive performance 3  Reduced mood  Increased incidence of and morbidity from infectious diseases 4  Thyroid dysfunction & impaired thermoregulation 5  Pregnancy: preterm delivery, low birth weight, reduced neonatal health 6 References: 1. Leitgeb C et al . Cancer 1994: 2535-2542 2. Schreiber S et al . NEJM 1996:619-623 3. Beard JL et al . Am J Clin Nut 2007:778-787 4. Basta SS et al . Am J Clin Nut1979: 916-925 5. Dillman E et al . Am J Physio 1980:R377-381 6. Allen LH et al . Am J Clin Nut 2000:1280S-4S

  5. Causes of anaemia in IBD  Iron Deficiency Anaemia  Anaemia of Chronic Disease  Vitamin B 12 / folate deficiency 1  Haemolysis 2  Myelodysplastic syndrome 3  Drug-induced:  Thiopurine 4  Sulfasalazine 5  Methotrexate 6 References: 1. Fernandez-Banares F et al . Am. J. Gastroenterol 1989 ;84(7):744-8. 2. Bell DW et al . South Med. J., 1981;74(3):359-61. 3. Wang, Z et al . Dig. Dis. Sci. 2008 ;53(7):1929-32. 4. Corominas H et al. Med. Clin. (Barc.) 2000 ;115(8):299-301 5. Dunn AM et al . Lancet 1981 ;2(8258):1288. 6. Bellaiche G et al. Gastroenterol. Clin. Biol. 1999 ;23(10):1102-3.

  6. Screening bloods  Full blood count  Haptoglobin  MCV  Lactate dehydrogenase  Serum ferritin  Creatinine  Transferrin saturation  Reticulocyte count  CRP  Vitamin B 12  Folate

  7. Distribution of iron in adults  3-4 kg iron in human body

  8. Iron absorption Maximum absorption: 20mg per day

  9. Iron deficiency anaemia  Prevalence 45% 1  Causes:  Blood loss  1 ml blood = 0.5 mg iron  daily losses >4ml = iron deficiency  Poor nutritional uptake 2  Impaired iron absorption 3  SB Crohn’s disease References: 1. Gisbert JP et al . Am J Gastro 2008:1299-1307 2. Lomer MC et al . Br J Nutr 2004:141-148 3. Semrin G et al . Inflamm Bowel Dis 2006:1101-1106

  10. Iron deficiency anaemia: Treatment  Aims:  Hb rise of 2g/dL in 4 weeks  Normalisation of Hb, ferritin and TF saturation  Greatest improvement in QoL at 11→12 g/dL 1  Options:  Oral iron  Parenteral iron References: 1. Crawford J et al. Cancer 2000:888-895.

  11. Oral iron Iron requirements (Body weight (kg) x (target Hb* (g/dL) – actual Hb) x 2.4) + mg iron for stores # *Target Hb: for body weight below 35 kg = 13 g/dL; for body weight 35 kg and above = 15 g/dL # Depot iron: for body weight below 35 kg = 15 mg/kg body weight; for body weight 35 kg and above = 500 mg

  12. Oral iron (cont) Maximum absorption of elemental iron is 20mg per day Elemental iron content of iron salts Iron salt Dose Iron content (%) Iron content Cost Ferrous sulphate 200mg 30 65mg £1.07 (28) Ferrous fumarate 200mg 33 65mg £2.30 (84) Ferrous gluconate 300mg 11.6 35mg £1.93 (28)  Concerns:  Side effects / intolerance 2 : 21-52%  Toxic reactive oxygen species  Slow response References: 1. Micromedex Healthcare Series, 2007. Thomson Healthcare Inc 2. 1. Kerr DN et al. Lancet 1958;489-492

  13. Parenteral iron  Iron gluconate  Less stable, leading to labile iron release  higher risk of A/E  Maximum dose 125mg  Iron dextran (low molecular weight)  Dextran-related anaphylaxis; test dose required  Long infusion time; large doses  Long time interval before bioavailibility  Iron sucrose (venofer)  95% of iron utilised within 2-4 weeks  Maximum dose 600mg/week in 200mg infusions  Iron carboxymaltose (ferrinject)  Rapidly infused (1000mg in 15 mins); no test dose  Iron utilised within 6-9 days so lower risk of A/E

  14. Summary of parenteral iron preparations LMW iron Iron sucrose Iron Iron Blood dextran Venofer carboxymaltose isomaltose Cosmofer Ferrinject Monofer Maximum 20mg/kg 200mg 1000mg 20mg/kg single dose (20mg/kg) Rapid infusion No Yes (bolus) Yes Yes Test dose? Yes Initial No No Iron 50 mg/ml 20 mg/ml 50 mg/ml 100 mg/ml 200mg per concentration unit Vial volumes 2 & 10 5 2 & 10 1, 5 & 10 Cost £7.97 / £9.35 £19.10 / £95.50 £16.95 / £39.85 £84.75 / £169.50

  15. Parenteral iron (cont.) Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel disease. Gasche C et al. Inflamm Bowel Dis . 2007 Dec;13(12):1545-53. Statement 4A: “ The preferred route of iron supplementation in IBD is intravenous, even though many patients will respond to oral iron. Intravenous iron is more effective, better tolerated, and improves the quality of life to a greater extent than oral iron supplements.” (Grade A)

  16. Indications for intravenous iron  Haemoglobin <10g/dL  Intolerance to oral iron  Poor response to oral iron  Moderate-severe disease activity  Concomitant treatment with erythropoietic agent  Patient preference

  17. Anaemia of Chronic Disease  Causes:  Functional iron deficiency 1  Up-regulation of ferritin  Reduced transferrin  Inhibition of erythropoiesis 2  IL-1 & TNF- α produce toxic radicals  damage erythropoietin-producing cells  Inhibition of differentiation/proliferation of erythroid precursors 3  Interferon- α , - β , - γ , TNF- α and IL-1  Uptake and retention of iron in the reticulo-endothelial system 4  Interferon- γ , TNF- α and IL-6  Hepcidin References: 1. Macdougall IC et al. BMJ 1992:225-226 2. Faquin WC et al. Blood 1992:1987-1994 3. Theurl I et al. Blood 2006:4142-4148 4. Weiss G et al. NEJM 2005:1011-1023

  18. Iron absorption Maximum absorption: 20mg per day

  19. Identifying the cause of anaemia Ferritin ( μ g/L) Transferrin saturation Active No MCV MCH sTR (%) inflammation inflammation ↓ ↓ ↑ IDA <100 <30 <16 ACD >100 >100 <16 Normal Normal Normal or ↓

  20. Take home message  Ask carefully for symptoms of anaemia  Anaemia should raise concerns about disease activity  Oral iron only in mild anaemia and inactive disease  Do not overtreat with oral supplements  Early treatment  Intravenous iron is preferable

Recommend Documents


pre operative anaemia
Pre-operative Anaemia Colorectal and

Pre-operative Anaemia Colorectal and Orthopaedic Surgery Dr Simon Rang

the joys of living with dba diamond blackfan anaemia
The Joys of Living with DBA (Diamond

The Joys of Living with DBA (Diamond Blackfan Anaemia) By Helen Witham What

in children seen at rcwmch
in children seen at RCWMCH Martie Wege

Prevalence and mangement of anaemia in children seen at RCWMCH Martie Wege

aims and objectives
Aims and objectives Why is haematology

Aims and objectives Why is haematology so difficult? Classification of

relationship between dermatoglyphics and
RELATIONSHIP BETWEEN DERMATOGLYPHICS

RELATIONSHIP BETWEEN DERMATOGLYPHICS AND SICKLE CELL ANAEMIA JAMES NKETSIAH

commitment
CoMMiTMenT Combined Molecular

CoMMiTMenT Combined Molecular Microscopy for Therapy and Personalized

aims and objectives
Aims and objectives Recap of

Aims and objectives Recap of haematology: anaemia, malignancies and clotting

deficiency anaemia
Deficiency Anaemia Dr Emma ODonovan

Pre-op Correction of Iron Deficiency Anaemia Dr Emma ODonovan Haematology

from office to om office to off label off label managing
From Office to om Office to Off-Label:

1 2 From Office to om Office to Off-Label: Off-Label: Managing Managing

managing broker regional roundtables
MANAGING BROKER REGIONAL ROUNDTABLES 1

MANAGING BROKER REGIONAL ROUNDTABLES 1 Presentation Overview The role of

building momentum for patients with myelofibrosis
Building Momentum for Patients with

Building Momentum for Patients with Myelofibrosis ASH Annual Meeting

kdigo
KDIGO Diagnostic tests and therapeutic

KDIGO Diagnostic tests and therapeutic targets for anemia of CKD Dorine W.

case reports uncommon presentation of pernicious anemia
Case Reports Uncommon Presentation of

American Journal of Hospital Medicine Promoting research and education in the

aplastic anemia
Aplastic Anemia Emma Groarke, MD,

Aplastic Anemia Emma Groarke, MD, FRCPath Staff Clinician, Bone Marrow

ohsu
OHSU Tom DeLoughery, MD MACP FAWM

Abnormal CBC OHSU Tom DeLoughery, MD MACP FAWM Oregon Health and Sciences

myelofibrosis new treatment strategies
Myelofibrosis: new treatment

Myelofibrosis: new treatment strategies Jeanne Palmer Mayo Clinic Arizona

mds
MDS The Stuart Goldberg MD

What you need to know about MDS The Stuart Goldberg MD Myelodysplastic

making the most out of the cbc making the most out of the
Making the most out of the CBC Making

Making the most out of the CBC Making the most out of the CBC and peripheral

the medalist trial results of a phase 3 randomized double
The MEDALIST Trial: Results of a Phase

The MEDALIST Trial: Results of a Phase 3, Randomized, Double-Blind,

provide comprehensive care at
provide comprehensive care at CHAM

Sickle Cell Anemia -striving to provide comprehensive care at CHAM Kerry